UK markets close in 1 hour
  • FTSE 100

    7,123.50
    -188.82 (-2.58%)
     
  • FTSE 250

    18,459.28
    -579.51 (-3.04%)
     
  • AIM

    873.12
    -20.20 (-2.26%)
     
  • GBP/EUR

    1.1672
    +0.0065 (+0.56%)
     
  • GBP/USD

    1.2168
    +0.0046 (+0.38%)
     
  • BTC-GBP

    15,573.71
    -1,023.71 (-6.17%)
     
  • CMC Crypto 200

    405.47
    -26.00 (-6.03%)
     
  • S&P 500

    3,751.46
    -67.37 (-1.76%)
     
  • DOW

    30,554.26
    -475.05 (-1.53%)
     
  • CRUDE OIL

    106.91
    -2.87 (-2.61%)
     
  • GOLD FUTURES

    1,816.10
    -1.40 (-0.08%)
     
  • NIKKEI 225

    26,393.04
    -411.56 (-1.54%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,650.73
    -352.62 (-2.71%)
     
  • CAC 40

    5,878.39
    -153.09 (-2.54%)
     

How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

With a market capitalization of US$106m, Adverum Biotechnologies is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Adverum Biotechnologies.

View our latest analysis for Adverum Biotechnologies

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Adverum Biotechnologies?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Adverum Biotechnologies does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Adverum Biotechnologies' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. It looks like hedge funds own 15% of Adverum Biotechnologies shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. FMR LLC is currently the company's largest shareholder with 11% of shares outstanding. RTW Investments, LP is the second largest shareholder owning 7.6% of common stock, and BlackRock, Inc. holds about 7.4% of the company stock. Furthermore, CEO Laurent Fischer is the owner of 0.8% of the company's shares.

We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Adverum Biotechnologies

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

We can see that insiders own shares in Adverum Biotechnologies, Inc.. As individuals, the insiders collectively own US$1.9m worth of the US$106m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

With a 18% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Adverum Biotechnologies. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 5.1% stake in Adverum Biotechnologies. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Adverum Biotechnologies , and understanding them should be part of your investment process.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting